The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Stepwise prolongation of overall survival from first- to third-generation EGFR-tyrosine kinase inhibitors in non-small cell lung cancer and the prognostic impact of concomitant antacids.
 
Kiyoaki Uryu
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Kyowa Hakko Kirin Co Ltd.; Nippon Boehringer Ingelheim; Nippon Kayaku
 
Yoshinori Imamura
Speakers' Bureau - Daiichi Sankyo/UCB Japan; MSD
 
Rai Shimoyama
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo/Astra Zeneca; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Maki Hayashi
No Relationships to Disclose
 
Megu Ohtaki
No Relationships to Disclose
 
Keiko Otani
No Relationships to Disclose
 
Hiromasa Harada
Speakers' Bureau - Astellas Pharma; GlaxoSmithKline
 
Hironobu Minami
Honoraria - Abbvie; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; Meiji Seika Kaisha; Merck; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Sanofi; Shionogi; Taiho Pharmaceutical; Takeda
Research Funding - Asahi Kasei (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Nihonkayaku (Inst); Nippon Shinyaku (Inst); Otsuka (Inst); Sanofi (Inst); Shionogi (Inst); Sumitomo Pharma Oncology (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst)